Fiasp (Novo Nordisk) is a faster insulin aspart with an earlier onset of action. In contrast to NovoLog, which is recommended to be dosed within 5-10 minutes before…
Read More
In response to findings of a safety signal report that there is reasonable suspicion of a causal association between use of Increlex® and childhood neoplasia, including malignancy,…
Read More
The FDA has approved two new ready to use forms of glucagon and these have been introduced to the market: an intranasal powder (Baqsimi, Eli Lilly)…
Read More
Vitamin D is a fat soluble vitamin that is essential for maintaining bone health and also has other potential health benefits. While some of these other…
Read More
Levothyroxine sodium oral solution (Tirosint-SOL) has now been approved by the FDA and is available for use in the US. Please click on the link below for…
Read More
Overview
The FDA recently approved a Safety Labeling Change (SLC) addressing the risk of necrolytic migratory erythema (NME) with continuous intravenous glucagon use. This change has been made because of case reports of NME, including three pediatric and three adult cases. All of the pediatric cases were also reported to the FDA Adverse Event Reporting System (FAERS). The first citation below contains two of the pediatric cases. One adult case (Mullans, et al.) was only available from the literature; the other two adult cases were also reported to FAERS. The FDA does not know the incidence of NME nor the incidence of off-label use of glucagon.
For the full wording of the label change, please log in.
Not a member?